Critical role of miR-10b in B-RafV600E dependent anchorage independent growth and invasion of melanoma cells.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 05 09 2018
accepted: 19 03 2019
entrez: 18 4 2019
pubmed: 18 4 2019
medline: 18 12 2019
Statut: epublish

Résumé

Recent high-throughput-sequencing of cancer genomes has identified oncogenic mutations in the B-Raf genetic locus as one of the critical events in melanomagenesis. B-Raf encodes a serine/threonine kinase that regulates the MAPK/ERK kinase (MEK) and extracellular signal-regulated kinase (ERK) protein kinase cascade. In normal cells, the activity of B-Raf is tightly regulated and is required for cell growth and survival. B-Raf gain-of-function mutations in melanoma frequently lead to unrestrained growth, enhanced cell invasion and increased viability of cancer cells. Although it is clear that the invasive phenotypes of B-Raf mutated melanoma cells are stringently dependent on B-Raf-MEK-ERK activation, the downstream effector targets that are required for oncogenic B-Raf-mediated melanomagenesis are not well defined. miRNAs have regulatory functions towards the expression of genes that are important in carcinogenesis. We observed that miR-10b expression correlates with the presence of the oncogenic B-Raf (B-RafV600E) mutation in melanoma cells. While expression of miR-10b enhances anchorage-independent growth of B-Raf wild-type melanoma cells, miR-10b silencing decreases B-RafV600E cancer cell invasion in vitro. Importantly, the expression of miR-10b is required for B-RafV600E-mediated anchorage independent growth and invasion of melanoma cells in vitro. Taken together our results suggest that miR-10b is an important mediator of oncogenic B-RafV600E activity in melanoma.

Identifiants

pubmed: 30995246
doi: 10.1371/journal.pone.0204387
pii: PONE-D-18-26080
pmc: PMC6469749
doi:

Substances chimiques

MIRN10 microRNA, human 0
MicroRNAs 0
RNA, Neoplasm 0
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0204387

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Pigment Cell Melanoma Res. 2010 Apr;23(2):190-200
pubmed: 20149136
Nature. 2010 Dec 16;468(7326):973-7
pubmed: 21107323
Cancer Res. 1999 Jun 1;59(11):2747-53
pubmed: 10364001
J Transl Med. 2010 Apr 20;8:39
pubmed: 20406486
Oncogene. 2005 May 12;24(21):3535-40
pubmed: 15782137
Cell. 2008 Feb 8;132(3):363-74
pubmed: 18267069
Mol Cancer. 2016 Nov 16;15(1):72
pubmed: 27852308
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Int J Cancer. 2009 Feb 15;124(4):911-8
pubmed: 19035444
Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498
pubmed: 23830918
Nature. 2007 Oct 11;449(7163):682-8
pubmed: 17898713
Mol Cell. 2014 Oct 2;56(1):104-15
pubmed: 25263593
N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
Cancer Cell. 2004 Oct;6(4):313-9
pubmed: 15488754
Sci Rep. 2014 Dec 16;4:7498
pubmed: 25510966
Cancer Res. 2016 Nov 1;76(21):6424-6435
pubmed: 27569213
Oncol Lett. 2015 Jan;9(1):15-24
pubmed: 25435928
Oncogene. 2010 Jan 7;29(1):81-92
pubmed: 19784067
Cell. 2008 Jun 13;133(6):1019-31
pubmed: 18555778
Cell. 2008 Jun 13;133(6):1006-18
pubmed: 18555777
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Mod Pathol. 2016 Feb;29(2):112-21
pubmed: 26743475
Cancer Res. 2012 Dec 15;72(24):6382-92
pubmed: 23222305
Nucleic Acids Res. 1995 May 25;23(10):1686-90
pubmed: 7784172
Int J Cell Biol. 2012;2012:913242
pubmed: 22611400
Cell Death Differ. 2010 Feb;17(2):209-14
pubmed: 19461655
Lab Invest. 1993 Feb;68(2):192-203
pubmed: 7680081
Cancer Cell. 2008 Jul 8;14(1):79-89
pubmed: 18598946
Cancer Res. 2004 Aug 1;64(15):5270-82
pubmed: 15289333
J Cancer. 2017 Aug 2;8(13):2487-2491
pubmed: 28900486
Carcinogenesis. 2013 Sep;34(9):2000-9
pubmed: 23689353

Auteurs

Ila Datar (I)

Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States of America.

Gardiyawasam Kalpana (G)

Department of Cancer Biology, College of Medicine and Life Sciences, University of Toledo, Health Science Campus, Toledo, OH, United States of America.

Jungmin Choi (J)

Department of Genetics, Yale School of Medicine, New Haven, CT, United States of America.

Tupa Basuroy (T)

Department of Cancer Biology, College of Medicine and Life Sciences, University of Toledo, Health Science Campus, Toledo, OH, United States of America.

Robert Trumbly (R)

Department of Cancer Biology, College of Medicine and Life Sciences, University of Toledo, Health Science Campus, Toledo, OH, United States of America.

Sri Krishna Chaitanya Arudra (SK)

Department of Pathology, Sanford Hospital, Bismarck, ND, United States of America.

Michael D McPhee (MD)

ProMedica Cancer Institute, Toledo, OH, United States of America.

Ivana de la Serna (I)

Department of Cancer Biology, College of Medicine and Life Sciences, University of Toledo, Health Science Campus, Toledo, OH, United States of America.

Kam C Yeung (KC)

Department of Cancer Biology, College of Medicine and Life Sciences, University of Toledo, Health Science Campus, Toledo, OH, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH